Roble, Belko & Company, Inc Mirum Pharmaceuticals, Inc. Transaction History
Roble, Belko & Company, Inc
- $627 Million
- Q1 2025
A detailed history of Roble, Belko & Company, Inc transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 19 shares of MIRM stock, worth $860. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19
Previous 19
-0.0%
Holding current value
$860
Previous $1,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding MIRM
# of Institutions
223Shares Held
55.4MCall Options Held
27.4KPut Options Held
105K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$308 Million19.27% of portfolio
-
Janus Henderson Group PLC London, X04.77MShares$216 Million0.12% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$147 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$127 Million5.54% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.54MShares$115 Million0.0% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.66B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...